Atelvia

Atelvia is a brand name of risedronate, approved by the FDA in the following formulation(s):

ATELVIA (risedronate sodium - tablet, delayed release; oral)

• 
  Manufacturer: WARNER CHILCOTT
  
  Approval date: October 8, 2010
  
  Strength(s): 35MG ^[RLD]

Has a generic version of Atelvia been approved?

No. There is currently no therapeutically equivalent version of Atelvia available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Atelvia. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Pharmaceutical compositions containing geminal diphosphonates
  Patent 5,583,122
  Issued: December 10, 1996
  Inventor(s): Benedict; James J. & Perkins; Christopher M.
  Assignee(s): The Procter & Gamble Company
  Pharmaceutical compositions, useful for treating abnormal calcium and phosphate metabolism, which contain geminal-diphosphonic acid compounds; and a method of treating diseases characterized by abnormal calcium and phosphate metabolism utilizing these pharmaceutical compositions.
  
  Patent expiration dates:
  
  
  • December 10, 2013
    
    ✓ 
    Patent use: TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • June 10, 2014
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Dosage forms of risedronate
  Patent 5,622,721
  Issued: April 22, 1997
  Inventor(s): Dansereau; Richard J. & Mosher; Russell Y. & Axelrod; Douglas W. & Sietsema; William K.
  Assignee(s): The Procter & Gamble Company
  The present invention is directed to a novel enteric-coated oral dosage form of a risedronate active ingredient comprised of a safe and effective amount of a pharmaceutical composition which is comprised of a risedronate active ingredient and pharmaceutically-acceptable excipients. Said dosage forms prohibit the exposure of the risedronate active ingredient to the epithelial and mucosal tissues of the buccal cavity, pharynx, esophagus, and stomach and thereby protects said tissues from erosion, ulceration or other like irritation. Accordingly, the said dosage forms effect the delivery to the lower gastrointestinal tract of said human or other mammal of a safe and effective amount of the risedronate active ingredient, and substantially alleviate the esophagitis or esophageal irritation which occasionally accompanies the oral administration of risedronate active ingredients.
  
  Patent expiration dates:
  
  
  • April 21, 2014
    
    ✓ 
    Patent use: TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
    ✓ 
    Drug product
  
  



• 
  Dosage forms of bisphosphonates
  Patent 7,645,459
  Issued: January 12, 2010
  Inventor(s): Dansereau; Richard John & Burgio, Jr.; David Ernest
  Assignee(s): The Procter & Gamble Company
  Oral dosage forms of a bisphosphonate comprised of a safe and effective amount of a pharmaceutical composition comprising a bisphosphonate, a chelating agent, and, means for effecting delayed release of the bisphosphonate and the chelating agent in the lower gastrointestinal tract provide delivery of the pharmaceutical composition to the lower gastrointestinal tract of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or beverages. The present invention substantially alleviates the interaction between bisphosphonates and food or beverages, which interaction results in the bisphosphonate active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food. Further, the present invention effects delivery of the bisphosphonate and the chelating agent to the lower GI tract, substantially alleviating the upper GI irritation associated with bisphosphonate therapies. These benefits simplify previously complex treatment regimens and can lead to increased patient compliance with bisphosphonate therapies.
  
  Patent expiration dates:
  
  
  • January 9, 2028
    
    ✓ 
    Patent use: TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
    ✓ 
    Drug product
  
  



• 
  Dosage forms of risedronate
  Patent 7,645,460
  Issued: January 12, 2010
  Inventor(s): Dansereau; Richard John & Burgio, Jr.; David Ernest
  Assignee(s): The Procter & Gamble Company
  Oral dosage forms of a risedronate comprised of a safe and effective amount of a pharmaceutical composition comprising risedronate, a chelating agent, and, means for effecting delayed release of the risedronate and the chelating agent in the small intestine provide immediate release of the pharmaceutical composition to the small intestine of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or beverages. The present invention substantially alleviates the interaction between risedronate and food or beverages, which interaction results in the bisphosphonate active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food. Further, the present invention effects delivery of risedronate and the chelating agent to the small intestine, substantially alleviating the upper GI irritation associated with bisphosphonate therapies. These benefits simplify previously complex treatment regimens and can lead to increased patient compliance with bisphosphonate therapies.
  
  Patent expiration dates:
  
  
  • January 9, 2028
    
    ✓ 
    Patent use: TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • October 8, 2013 - NEW DOSAGE FORM
  
  

See also...

• Atelvia Consumer Information (Drugs.com)
• Atelvia Delayed-Release Tablets Consumer Information (Wolters Kluwer)
• Atelvia Consumer Information (Cerner Multum)
• Atelvia Advanced Consumer Information (Micromedex)
• Risedronate Delayed-Release Tablets Consumer Information (Wolters Kluwer)
• Risedronate Tablets Consumer Information (Wolters Kluwer)
• Risedronate Consumer Information (Cerner Multum)
• Risedronate Advanced Consumer Information (Micromedex)
• Risedronate Sodium AHFS DI Monographs (ASHP)